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Abstract: Pregnant women colonized by Streptococcus agalactiae, or group B streptococcus (GBS),
are at an increased risk of premature delivery and stillbirth, and their neonates can be endangered
by the development of an invasive GBS disease. In this study, the results of the GBS screening
among pregnant women performed between 2012 and 2018 (n = 19267) are presented. For the
GBS positive samples, the antibiotic susceptibility of the isolated strains was also tested (n = 3554).
During the examined period, the colonization rate varied between 17.4% and 19.8%. The overall
rate of erythromycin and clindamycin resistance in the GBS positive samples was 34.9% and 34.6%,
respectively. The frequency of the erythromycin and clindamycin resistant strains showed an
increasing tendency. An analysis of the MALDI-TOF MS spectra of 260 GBS isolates revealed that
46.5% of them belonged to either the ST-1 or the ST-17 sequence types, indicating a high prevalence of
these potentially invasive GBS strains in our region. More than half of the strains identified as ST-1
(52.1%) proved to be resistant to erythromycin and clindamycin.
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1. Introduction
Streptococcus agalactiae (S. agalactiae), also known as group B streptococcus (GBS), may cause serious
infections in newborns, pregnant and postpartum women, and immunocompromised adults [1,2].
This Gram-positive β-haemolytic bacterium can cause urinary tract infections, fever, chorioamnionitis,
endometritis, and puerperal sepsis in women [3–5], and it is among the leading causes of neonatal
invasive diseases in the United States and Europe [5–8]. Approximately 10%–30% of pregnant women
are colonized by GBS without any symptoms [6,9,10]. However, these women are at an increased
risk of premature delivery and stillbirth, and their newborns can be exposed to the development of
an invasive GBS disease [2,5]. Therefore, vaginal or rectal GBS colonization indicates intrapartum
antibiotic prophylaxis. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) is an effective method for the identification of GBS strains at the species level [11,12].
Moreover, MALDI-TOF MS also proven to be applicable to detect the S. agalactiae sequence types
ST-17 and ST-1 based on the characteristic peak-shifts present in their protein MS spectra [13]. Within
S. agalactiae, various sequence types could be discerned by the multi locus sequence typing (MLST)
method [11]. Among these MLST types, ST-17 is considered as highly virulent, and was found to
be one of the most frequent agents of neonatal meningitis and GBS late-onset-disease (LOD) [13–15].
Furthermore, ST-1 has become another significant cause of invasive neonatal infections, since its
emergence in the 1990s [13,15,16].
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The aim of the present study was to analyze the results of the GBS screening among pregnant
women and antibiotic susceptibility testing at the Albert Szent-Györgyi Clinical Center (University of
Szeged, Hungary) between 2012 and 2018. We also report our experiences in the application of the
rapid MALDI-TOF MS-based detection of ST-17 and ST-1 GBS.
2. Results
2.1. Colonization
During the examined period, vaginal or cervical samples of 19,267 pregnant women were screened
for S. agalactiae, among which 3554 samples proved to be GBS positive (Table 1). The colonization
rate showed only slight changes in the various years, and its value fluctuated between 17.4% and
19.8% (the mean value is 18.4%). Although much less samples (3566) were tested in the age group of
26–30 years than those (6510) in the age group of 31–35 years, the colonization rate was the same in
both groups (19%), which was the highest rate compared with the other age groups (Table 1). At the
same time, the colonization rate was higher than 10% in each age group.
Table 1. Number of screened and the group B streptococcus (GBS) positive samples and the colonization
rates measured in the different age groups during the examined period.
Age Groups (Years Old) <21 21–25 26–30 31–35 36–40 41–45 >45 Total
Year
2012 No. of screened samples 4 73 468 1037 823 357 114 2876
No. of GBS positive samples
(colonization rate; %)
0
(0)
10
(13.7)
80
(17.1)
196
(18.9)
150
(18.2)
53
(14.8)
17
(14.9)
506
(17.6)
2013 No. of screened samples 6 88 538 966 867 329 116 2910
No. of GBS positive samples
(colonization rate; %)
1
(16.7)
24
(27.3)
96
(17.8)
176
(18.2)
142
(16.4)
52
(15.8)
17
(14.7)
508
(17.5)
2014 No. of screened samples 10 94 539 1015 890 344 115 3007
No. of GBS positive samples
(colonization rate; %)
2
(20.0)
15
(16.0)
106
(19.7)
212
(20.9)
168
(18.9)
69
(20.1)
23
(20.0)
595
(19.8)
2015 No. of screened samples 3 103 557 992 884 352 89 2980
No. of GBS positive samples
(colonization rate; %)
0
(0)
16
(15.5)
101
(18.1)
198
(20.0)
177
(20.0)
67
(19.0)
17
(19.1)
576
(19.3)
2016 No. of screened samples 9 92 568 1001 866 341 89 2966
No. of GBS positive samples
(colonization rate; %)
2
(22.2)
17
(18.5)
123
(21.7)
193
(19.3)
160
(18.5)
57
(16.7)
18
(20.2)
570
(19.2)
2017 No. of screened samples 7 108 584 951 839 331 60 2880
No. of GBS positive samples
(colonization rate; %)
1
(14.3)
14
(13.0)
111
(19.0)
158
(16.6)
147
(17.5)
62
(18.7)
9
(15.0)
502
(17.4)
2018 No. of screened samples 3 75 312 548 480 197 33 1648
No. of GBS positive samples
(colonization rate; %)
0
(0)
13
(17.3)
59
(18.9)
109
(19.9)
85
(17.7)
27
(13.7)
4
(12.0)
297
(18.0)
Total No. of screened samples 42 633 3566 6510 5649 2251 616 19267
No. of GBS positive samples
(colonization rate; %)
6
(14.3)
109
(17.2)
676
(19.0)
1242
(19.0)
1029
(18.2)
387
(17.2)
105
(17.1)
3554
(18.5)
2.2. Antimicrobial Susceptibility Testing
In the case of the 3554 GBS positive samples, the susceptibility of the isolated strains to penicillin,
cefuroxime, vancomycin, erythromycin, clindamycin, and trimethoprim–sulfamethoxazole was also
tested. All of the tested strains proved to be susceptible to beta-lactams (i.e., penicillin and cefuroxime),
vancomycin, and trimethoprim–sulfamethoxazole. The overall frequency of the erythromycin and
clindamycin resistant isolates were 34.9% and 34.6%, respectively, while co-resistance to the two
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antibiotics was detected in 33.2% of the GBS positive samples (Table 2). However, between the years
2012 and 2018, the frequency of the erythromycin and clindamycin resistant GBS strains increased
from 29.2% and 30.2% to 39.7% and 38.7%, respectively, while the co-resistance level increased from
28% to 35.7% (Table 2). Only a low percentage of the isolated strains proved to be resistant to either
erythromycin or clindamycin alone (i.e., 1.9% and 1.4%, respectively) (Table 2). Inducible clindamycin
resistance was detected only in 6.5% of the isolated GBS strains.
Table 2. Number and proportion of erythromycin and clindamycin resistant strains isolated from the
GBS positive samples.
Year GBS
Positive
Samples
Erythromycin
Resistant
Strains (%)
Clindamycin
Resistant
Strains (%)
Strains Resistant
to Erythromycin
Alone (%)
Strains Resistant
to Clindamycin
Alone (%)
Erythromycin-
Clindamycin
Co-Resistant Strains (%)
2012 506 148 (29.2) 153 (30.2) 6 (1.2) 11 (2.2) 142 (28)
2013 508 172 (33.9) 170 (33.5) 6 (1.2) 4 (0.8) 166 (32.8)
2014 595 190 (31.9) 182 (30.6) 17 (2.9) 9 (1.5) 173 (29.1)
2015 576 222 (38.5) 221 (38.4) 11 (1.9) 10 (1.7) 211 (36.6)
2016 570 196 (34.4) 182 (31.9) 14 (2.5) 0 (0) 182 (31.9)
2017 502 206 (41.0) 206 (41.0) 6 (1.2) 6 (1.2) 200 (39.8)
2018 297 118 (39.7) 115 (38.7) 12 (4.0) 9 (3.0) 106 (35.7)
Total 3554 1239 (34.9) 1230 (34.6) 68 (1.9) 49 (1.4) 1181 (33.2)
2.3. ST-1 and ST-17 Detection
The presence of the protein peaks characteristic of the highly virulent invasive ST-1 and ST-17
clones was examined in the MS spectra of 260 randomly selected GBS strains isolated in 2017 and
2018. According to this analysis, 27.3% (71 strains) of the tested strains belonged to the ST-1 type,
and 19.2% (50 strains) proved to be ST-17 (Table 3). While the proportion of the erythromycin and
clindamycin co-resistant ST-17 strains (32%) did not differ significantly from that of the non-ST-1 and
non-ST-17 strains (30.9%), 52.1% of the 71 ST-1 strains proved to be resistant to both antibiotics (Table 3).
Moreover, all of these ST-1 strains were co-resistant to erythromycin and clindamycin. At the same
time, 2% and 2.9% of the ST-17 and the non-ST-1 and non-ST-17 strains, respectively, proved to be
resistant to clindamycin alone. The proportion of strains with induced clindamycin resistance was 4%
(two strains) for the ST-17, 5.6% (four strains) for the ST-1, and 7.9% (eleven strains) for the non-ST-1
and non-ST-17 strains. Erythromycin resistance alone was not detected among the 260 tested strains.
Table 3. Number and rate of the ST-1 and ST-17 strains detected by the analysis of the matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) spectra, and the number
and rate of the erythromycin and clindamycin resistant strains among them.
Sequence Type
No. of
Strains
Detected (%)
Erythromycin
Resistant
Strains (%)
Clindamycin
Resistant
Strains (%)
Strains Resistant
to Clindamycin
Alone (%)
Erythromycin-
Clindamycin
Co-Resistant Strains (%)
ST-1 71 (27.3) 37 (52.1) 37 (52.1) 0 (0) 37 (52.1)
ST-17 50 (19.2) 16 (32.0) 17 (34.0) 1 (2.0) 16 (32.0)
Other
(non-ST-1, non-ST-17) 139 (53.5) 43 (30.9) 47 (33.8) 4 (2.9) 43 (30.9)
3. Discussion
In our study, the GBS colonization level was found to be around 20% during the examined period.
This value falls into the range of the colonization rates (i.e., from 6.5% to 36%) reported earlier for
European countries [15,17], but it is somewhat higher than that reported recently in the neighboring
country, Serbia (15%) [18]. At the same time, this relatively high colonization rate emphasizes the
importance of the accurate GBS screening of pregnant women.
All of the GBS strains were susceptible to beta-lactams and vancomycin, which can be considered
as a common pattern observed in several previous studies [19–22]. At the same time, a high
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level of resistance to erythromycin and clindamycin, and a clearly increasing tendency in the
frequency of resistant strains has been observed over the years examined. Other studies have
also reported the spreading of macrolide and lincosamide resistance among the GBS strains [23–25],
and highlighted the need of susceptibility testing of colonizing GBS strains for an effective intrapartum
antibiotic prophylaxis [10–26]. The majority of erythromycin and clindamycin resistant strains
proved to be co-resistant to these antibiotics, and the majority of the detected clindamycin resistances
were constitutive.
The method of Lartigue et al. [13] was used for the MALDI-TOF MS-based detection of the ST-17
and ST-1 strains. These GBS sequence types have frequently been associated with neonatal meningitis
and invasive neonatal infections [15]. In our study, almost half (46.5%) of the examined S. agalactiae
strains proved to be either ST-1 (27.3%) or ST-17 (19.2%) clones, indicating a high prevalence of these
potentially virulent and invasive GBS strains in our region. It should be mentioned that, according to
Lartigue et al. [13], the sensitivity and specificity of this identification method were 100% and 95%,
respectively, for ST-1, and 100% and 98%, respectively, for ST-17.
ST-1 is thought to be the predominant colonizer in pregnant women, and found to be one of the
most frequent clones in vaginal samples [15,27,28]. Our study also indicates a significant distribution
of the ST-17 clone. Recently, Gajic et al. [18] found this sequence type as the most common clone in
Serbian samples. Moreover, the rate of erythromycin and clindamycin co-resistance was found to be
extremely high among the ST-1 clones (52.1%). Previously, Bergseng et al. [16] also found a strong
association of ST-1 clones and erythromycin resistance.
To our knowledge, this study is the first analysis of the GBS screening results and the antibiotic
susceptibility pattern of GBS strains colonizing pregnant women in our region, and the first data about
the frequency of highly virulent ST-1 and ST-17 GBS clones in Hungary.
Our work demonstrates the value and usefulness of MALDI-TOF MS analysis in GBS screening,
and reinforces that the examination of the MALDI-TOF MS spectra is a useful method to detect the
potentially invasive ST-1 and ST-17 GBS clones. The high frequency of these clones in our samples
indicates the importance of the accurate S. agalactiae screening of pregnant women, because almost half
of GBS-positive pregnant women can be colonized by these highly virulent clones in our region.
4. Materials and Methods
4.1. Research Design and Samples
The study was conducted in the Albert Szent-Györgyi Clinical Center (University of Szeged,
Hungary), and was approved by the institutional review board (no. 197/2017-SZTE). GBS screenings
were performed on vaginal or cervical samples of all of the pregnant women aged from 14 to 58 years
(n = 19,267) who attended at the clinical center to detect their GBS colonization status from January
2012 to July 2018. For each GBS positive sample, antibiotic susceptibility of the isolated GBS strain was
tested (n = 3554). From the strains isolated from January 2017 to July 2018, 260 isolates were randomly
selected and subjected to ST-1 and ST-17 detection.
4.2. GBS Screening of Pregnant Women
GBS screening was performed according to the CDC 2010 guideline [10] in each case. Samples were
inoculated onto Columbia agar plates containing 5% sheep blood (bioMérieux, France), and incubated
at 35–37 ◦C in 5% CO2. In parallel, a selective enrichment was also performed in modified Todd
Hewitt broth (OXOID, England) supplemented with nalidixic acid (0.015 g/L) and colistin (0.010 g/L)
at 35–37 ◦C in 5% CO2. After incubation for 18–24 h, the enriched broth was plated onto CHROMagar
StrepB (CHROMagar, France) and subcultured at 37 ◦C under aerobic conditions for 18, 24, or 48 h.
After incubation, the Columbia agar or CHROMagar StrepB plates were inspected to detect suspicious
colonies. The presumptive GBS colonies were identified by MALDI-TOF MS or by traditional methods
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(i.e., colony morphology, beta-haemolysis, bacitracin resistance, CAMP test, and Lancefield-group B
detection by latex agglutination test with Pastorex Strep Kit [Bio-Rad, France]).
4.3. MALDI-TOF MS Analysis
For the species level identification of the isolated bacterial colonies, a MALDI-TOF MS analysis
was performed using a MALDI Biotyper system (Bruker Daltonik GmbH, Germany) in the positive
linear mode across the m/z range of 2 to 20 kDa. For each spectrum, 240 laser shots at 60 Hz in groups
of 40 shots per sampling area were collected. The spectra were analyzed by the MALDI Biotyper RTC
3.1 software (Bruker Daltonics, Germany), using the MALDI Biotyper Library 3.1. The ST-1 and ST-17
sequence types were identified by examining the MS spectra of the selected strains and detecting the
presence of the 6250-Da protein specific to ST-1 or the 7625-Da protein specific to ST-17, according to
the method described by Lartigue et al. [13].
4.4. Antibiotic Susceptibility Testing
Antimicrobial susceptibility was tested to penicillin, cefuroxime, vancomycin, trimethoprim–
sulfamethoxazole, erythromycin, and clindamycin. The testing was performed by the disk diffusion
method, according to the recommendations of The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) (http://www.eucast.org/; [29]).
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